James H. MacKaness Net Worth

The estimated Net Worth of James H Mackaness is at least $9.95 Millón dollars as of 28 August 2024. Mr Mackaness owns over 13,531 units of Soleno Therapeutics Inc stock worth over $6,181,756 and over the last 16 years he sold SLNO stock worth over $3,573,687. In addition, he makes $198,988 as Chief Financial Officer at Soleno Therapeutics Inc.

Mr MacKaness SLNO stock SEC Form 4 insiders trading

Mr has made over 37 trades of the Soleno Therapeutics Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently he sold 13,531 units of SLNO stock worth $641,775 on 28 August 2024.

The largest trade he's ever made was buying 40,000 units of Soleno Therapeutics Inc stock on 31 March 2022 worth over $1,943,200. On average, Mr trades about 5,336 units every 103 days since 2008. As of 28 August 2024 he still owns at least 127,249 units of Soleno Therapeutics Inc stock.

You can see the complete history of Mr Mackaness stock trades at the bottom of the page.

Mr. James H. MacKaness biography

James H. MacKaness is the Chief Financial Officer at Soleno Therapeutics Inc.

What is the salary of Mr MacKaness?

As the Chief Financial Officer of Soleno Therapeutics Inc, the total compensation of Mr MacKaness at Soleno Therapeutics Inc is $198,988. There are 4 executives at Soleno Therapeutics Inc getting paid more, with Anish Bhatnagar having the highest compensation of $822,089.

How old is Mr MacKaness?

Mr MacKaness is 57, he's been the Chief Financial Officer of Soleno Therapeutics Inc since . There are 4 older and 5 younger executives at Soleno Therapeutics Inc. The oldest executive at Soleno Therapeutics Inc is Ernest Mario, 81, who is the Independent Chairman of the Board.

What's Mr MacKaness's mailing address?

James's mailing address filed with the SEC is 203 REDWOOD SHORES PKWY, STE 500, , REDWOOD CITY, CA, 94065.

Insiders trading at Soleno Therapeutics Inc

Over the last 9 years, insiders at Soleno Therapeutics Inc have traded over $134,327,999 worth of Soleno Therapeutics Inc stock and bought 56,592,152 units worth $70,324,676 . The most active insiders traders include Advisors Llcperceptive Life..., Jack W Schuler y Andrew Sinclair. On average, Soleno Therapeutics Inc executives and independent directors trade stock every 29 days with the average trade being worth of $36,911,570. The most recent stock trade was executed by Kristen Yen on 28 August 2024, trading 10,705 units of SLNO stock currently worth $507,738.

What does Soleno Therapeutics Inc do?

soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.

Complete history of Mr Mackaness stock trades at IRIDEX y Soleno Therapeutics Inc

Soleno Therapeutics Inc executives and stock owners

Soleno Therapeutics Inc executives and other stock owners filed with the SEC include:

• Anish Bhatnagar,
  President, Chief Executive Officer, Director
• Dr. Anish Bhatnagar,
  Pres, CEO, COO & Director
• Patricia Hirano,
  Vice President - Regulatory Affairs
• Kristen Yen,
  Vice President - Clinical Operations
• James H. MacKaness,
  Chief Financial Officer
• Ernest Mario,
  Independent Chairman of the Board
• William Harris,
  Independent Director
• Gwen Melincoff,
  Independent Director
• Birgitte Volck,
  Independent Director
• Andrew Sinclair,
  Independent Director
• Dr. Neil M. Cowen M.B.A., Ph.D., MBA,
  Sr. VP of Drug Devel.
• Anthony Wondka,
  Sr. VP & GM
• Dawn Carter Bir,
  
• Jack W Schuler,
  
• Larry N Feinberg,
  10% owner
• Opportunity, Llc Vivo Oppor...,
  
• Jonathan Wolter,
  Chief Financial Officer
• Stephen Kirnon,
  Director
• Mahendra Shah,
  Director
• Rajen Dalal,
  Director
• Edgar Engleman,
  Director
• Ventures V, Llc Vivo,
  10% owner
• Steinar J Engelsen,
  Director
• James Walter Glasheen,
  Director
• Stuart J Collinson,
  Director
• Ventures V, Llc Vivo Ventur...,
  
• Raymond W. Urbanski,
  CHIEF DEVELOPMENT OFFICER
• Management Vii Llctechnolog...,
  
• Mangement Llcbioasia Invest...,
  
• Larry Noracle Partners Lp F...,
  
• Llp Abingworth,
  10% owner
• Ventures V, Llc Vivo Ventur...,
  
• Group Inc.Carlyle Holdings ...,
  
• Meredith Manning,
  Chief Commercial Officer
• Michael F. Huang,
  Sr. VP of Clinical Development
• Matthew Pauls,
  
• Group Inc.Carlyle Holdings ...,
  
• Advisors Llcperceptive Life...,
  
• James H Mackaness,
  CHIEF FINANCIAL OFFICER